{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:23:38Z","timestamp":1754486618804},"reference-count":33,"publisher":"SLACK, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>\n            Recent widely publicized shortages in the U.S. supply of first-line medications for treatment of attention-deficit\/hyperactivity disorder (ADHD) are thought to reflect increases in public awareness, help seeking, and treatment. ADHD is one of the most common neurodevelopmental disorders and is typically identified in childhood. In adulthood, ADHD symptoms are less likely to include hyperactivity, but inattention, impulsivity, and emotional dysregulation are common. Clinical evaluation of symptomatic adults who were not diagnosed as children requires corroboration of ADHD diagnostic symptoms in childhood and careful differentiation of ADHD from frequently co-occurring psychiatric and substance use disorders. Treatment of adult ADHD can result in improved functioning across multiple dimensions and comorbid disorders. Existing guidelines and consensus statements recommend an integrated approach to treating ADHD and all existing comorbid disorders, prioritizing the disorder that is creating the most difficulty for the individual. [\n            <jats:italic>Journal of Psychosocial Nursing and Mental Health Services, 62<\/jats:italic>\n            (1), 8\u201311.]\n          <\/jats:p>","DOI":"10.3928\/02793695-20231212-01","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T21:32:12Z","timestamp":1704403932000},"page":"8-11","source":"Crossref","is-referenced-by-count":2,"title":["Reducing Risk in the Treatment of Attention-Deficit\/Hyperactivity Disorder Among Adults With Comorbidities"],"prefix":"10.3928","volume":"62","author":[{"given":"Karan","family":"Kverno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Ramos-Marcuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/nty059"},{"key":"e_1_3_1_3_1","author":"American Professional Society of ADHD and Related Disorders","year":"2023","unstructured":"American Professional Society of ADHD and Related Disorders. (2023, August). The first U.S. guidelines for adult ADHD to be released by the American Professional Society of ADHD and related disorders (APSARD.org). https:\/\/apsard.org\/wp-content\/uploads\/2022\/08\/APSARD-Adult-ADHD-Guidelines-Press-Release.pdf","journal-title":"The first U.S. guidelines for adult ADHD to be released by the American Professional Society of ADHD and related disorders (APSARD.org)"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093096"},{"key":"e_1_3_1_6_1","volume-title":"Barkley Adult ADHD Rating Scale-IV (BAARS-IV)s","author":"Barkley R. A.","year":"2011","unstructured":"Barkley, R. A. (2011). Barkley Adult ADHD Rating Scale-IV (BAARS-IV)s. The Guilford Press."},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-016-0750-x"},{"key":"e_1_3_1_8_1","author":"Centers for Disease Control and Prevention","year":"2022","unstructured":"Centers for Disease Control and Prevention. (2022). Attention deficit hyperactivity disorder (ADHD). https:\/\/www.cdc.gov\/nchs\/fastats\/adhd.htm#print","journal-title":"Attention deficit hyperactivity disorder (ADHD)"},{"key":"e_1_3_1_9_1","author":"Centers for Disease Control and Prevention","year":"2023","unstructured":"Centers for Disease Control and Prevention. (2023, August 23). Stimulant overdose. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/stimulant-overdose.html#:\u223c:text=Rates%20of%20overdose%20deaths%20from,deaths%20in%202021%20involved%20psychostimulants","journal-title":"Stimulant overdose"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277175"},{"key":"e_1_3_1_11_1","volume-title":"Conners' Adult ADHD Rating Scales (CAARS): ADHD across the life span","author":"Conners C. K.","year":"1998","unstructured":"Conners, C. K., Erhardt, D. & Sparrow, E. (1998). Conners' Adult ADHD Rating Scales (CAARS): ADHD across the life span. Multi-Health Systems, Inc."},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000487767"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.022"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1011620"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.3788"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1463-3"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0175-1"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291704002892"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2018.11.001"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13803395.2021.1950640"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.07.010"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13854046.2019.1696409"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109906"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14506-w"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","unstructured":"Park T. W. Baul T. D. Morgan J. R. Wilens T. E. & Yule A. M. (2023). Trends in attention-deficit hyperactivity disorder diagnosis and pharmacotherapy among adults with opioid use disorder. Psychiatric Services (Washington D.C.). Advance online publication. 10.1176\/appi.ps.20220400 PMID:37789727","DOI":"10.1176\/appi.ps.20220400"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20021275"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57050466"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000604"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-021-01159-w"},{"key":"e_1_3_1_30_1","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. (2017, May 30). FDA approves first generic Strattera for the treatment of ADHD. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-strattera-treatment-adhd","journal-title":"FDA approves first generic Strattera for the treatment of ADHD"},{"key":"e_1_3_1_31_1","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration. (2023, May). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions: Serious risks with misuse, abuse, addiction, and sharing these drugs. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions","journal-title":"FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions: Serious risks with misuse, abuse, addiction, and sharing these drugs"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","unstructured":"Zhang L. Li L. Andell P. Garcia-Argibay M. Quinn P. D. D'Onofrio B. M. Brikell I. Kuja-Halkola R. Lichtenstein P. Johnell K. Larsson H. & Chang Z. (2023). Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. Advance online publication. 10.1001\/jamapsychiatry.2023.4294 PMID:37991787","DOI":"10.1001\/jamapsychiatry.2023.4294"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43597"},{"key":"e_1_3_1_34_1","author":"Zorn S. Z.","year":"2015","unstructured":"Zorn, S. Z. (2015, April 28). The safety of stimulant medication use in cardiovascular and arrythmia patients. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2015\/04\/28\/10\/06\/the-safety-of-stimulant-medicationuse-in-cardiovascular-and-arrhythmia-patients#:\u223c:text=Furthermore%2C%20the%20FDA%20issued%20a,(HR)%20would%20be%20problematic","journal-title":"The safety of stimulant medication use in cardiovascular and arrythmia patients"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T21:32:20Z","timestamp":1704403940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20231212-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.3928\/02793695-20231212-01"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20231212-01","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}